{
    "body": "Which treatment leads to an increase in neutrophil counts in severe congenital neutropenia?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/7529539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2683920", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1705835", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1689595", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21052952", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16822461"
    ], 
    "ideal_answer": [
        "In phase I/II/III studies in patients with severe congenital and cyclic neutropenia, treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) resulted in a rise in the absolute neutrophil counts (ANC) and a reduction in infections  ", 
        "In patients with severe congenital and cyclic neutropenia, treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) resulted in a rise in the absolute neutrophil counts (ANC) and a reduction in infections."
    ], 
    "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:0050590"
    ], 
    "type": "summary", 
    "id": "550313aae9bde6963400001f", 
    "snippets": [
        {
            "offsetInBeginSection": 173, 
            "offsetInEndSection": 441, 
            "text": "This chapter focuses on cyclic and congenital neutropenia, two very interesting and rare hematological conditions causing severe chronic neutropenia. Both disorders respond well to treatment with the myeloid growth factor, granulocyte colony-stimulating factor (G-CSF)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21052952", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1176, 
            "offsetInEndSection": 1474, 
            "text": "Data on more than 600 patients with CN collected by the Severe Chronic Neutropenia International Registry (SCNIR) demonstrate that, regardless of the particular CN subtype, more than 95% of these patients respond to recombinant human (rHu)G-CSF with ANCs that can be maintained above 1.0 x 10(9)/L.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16822461", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 153, 
            "text": "Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/7529539", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 121, 
            "offsetInEndSection": 380, 
            "text": "In phase I/II/III studies in patients with severe congenital and cyclic neutropenia, treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) resulted in a rise in the absolute neutrophil counts (ANC) and a reduction in infections", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/7529539", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 541, 
            "offsetInEndSection": 660, 
            "text": "A sustained ANC response was seen in 40/44 severe congenital neutropenia patients and 10/10 cyclic neutropenia patients", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/7529539", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 200, 
            "offsetInEndSection": 433, 
            "text": "We examined peripheral blood mononuclear cells (PBMC) of SCN patients who demonstrated normalization of their blood neutrophil counts in a phase II clinical study with recombinant human granulocyte colony-stimulating factor (rhG-CSF)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/1705835", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 166, 
            "text": "Severe congenital neutropenia (SCN) is a disorder of myelopoiesis characterized by severe neutropenia secondary to a maturational arrest at the level of promyelocytes", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/1689595", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 942, 
            "offsetInEndSection": 1170, 
            "text": "In contrast to rhGM-CSF treatment, all five patients responded to rhG-CSF during the first 6 weeks of treatment with an increase in the ANC to above 1,000/microL. The level of ANC could be maintained during maintenance treatment", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/1689595", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 256, 
            "offsetInEndSection": 470, 
            "text": "Treatment of these patients with granulocyte colony-stimulating factor (G-CSF) leads to a significant increase in circulating neutrophils and a reduction in infection-related events in more than 95% of the patients", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/10779444", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1256, 
            "offsetInEndSection": 1333, 
            "text": "In patients with chronic neutropenia, rhGM-CSF may increase neutrophil counts", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/2683920", 
            "endSection": "abstract"
        }
    ]
}